Tislelizumab plus Gemox in relapsed or refractory patients with cHL: a multicentre, single-arm, phase 2 trial
Latest Information Update: 25 Jan 2022
At a glance
- Drugs Tislelizumab (Primary) ; Gemcitabine; Oxaliplatin
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 14 Dec 2021 Status changed from not yet recruiting to recruiting, as per results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results (n=22; data cut off: July 2021) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 31 Jul 2020 New trial record